CD47 is a Potential Target for the Treatment of Laryngeal Squamous Cell Carcinoma

Yang, Chunping; Gao, Shufeng; Zhang, Haizhen; Xu, Liang; Liu, Jianguo; Wang, Meiqun; Zhang, ShaoRong

doi:10.1159/000452530

Cited by 12 publications

(9 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IHC staining confirmed that CD47 was highly expressed in the tumor cells of patients with ESCC. These results are consistent with previously published data in which CD47 levels in tumor tissues were significantly higher than those in non-tumor tissues in patients with ESCC or LSCC (34,35). In addition, increased levels of tumor tissue infiltration by macrophages were observed in the current study.…”

Section: Discussionsupporting

confidence: 94%

Characterization of cluster of differentiationï¿½47 expression and its potential as a therapeutic target in esophageal squamous cell cancer

Zhao

Wang

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. The increased expression of cluster of differentiation (CD)47 has been identified in a number of different tumor types and is recognized as an adverse prognostic factor that indicates an increased risk of mortality in patients. The binding of CD47 to signal regulatory protein α (SIRPα) inhibits the macrophage phagocytosis of tumor cells by triggering an inhibitory 'do not eat me' signal. This is one of the mechanisms used by tumor cells to evade immune surveillance. In the present study, CD47 levels and macrophage infiltration were assessed in patients with esophageal squamous cell cancer (ESCC). CD47-overexpressing ESCC cell lines were selected and human M2 macrophage phagocytic activity was measured. The results revealed that CD47 is highly expressed and macrophages are markedly infiltrated in cancerous tissue compared with non-cancerous tissue. High CD47 expression was detected in ESCC cell lines and the results of a phagocytosis assay indicated that human M2 macrophages phagocytized tumor cells in a dose-dependent manner following the blocking of CD47-SIRPα signaling by anti-CD47 antibodies. The results of the present study therefore support the use of anti-CD47 immunotherapy to treat patients with ESCC.

show abstract

Section: Discussionsupporting

confidence: 94%

Characterization of cluster of differentiationï¿½47 expression and its potential as a therapeutic target in esophageal squamous cell cancer

Zhao

Wang

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Metabolism agents with anti-tumor effects, such as metformin, may decrease M2-like abundance and polarization (61). Inhibition of the interaction between CD47, a marker of self upregulated by tumor cells in the TME, and SIRPα, a surface molecule on TAMs, enhances phagocytosis and decreases the M2/M1 ratio (62). Humanized anti-CD40 antibodies have been shown to re-educate M2-like TAMs to become M1-like, and induce tumor regression and improve survival in pancreatic cancer mouse models and surgically incurable patients (63).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of Tumor-Associated Macrophage Content in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis

et al. 2019

View full text Add to dashboard Cite

Background: Head and neck squamous cell carcinoma (HNSCC) exists within a microenvironment rich in immune cells. Macrophages are particularly abundant in and around tumor tissue, and have been implicated in the growth, malignancy, and persistence of HNSCC ( 1 ). However, current literature reports variable degrees of association between the density of tumor-associated macrophages (TAMs) and clinicopathologic markers of disease ( 2 , 3 ). These inconsistent findings may be a result of differences in approach to TAM detection. Authors have measured total TAMs in tumor tissue, while others have stained tumor samples for individual subtypes of TAMs, which include pro-inflammatory (M1-like) and immunosuppressive (M2-like). Our aim is to more clearly define the prognostic significance of the phenotypes of tumor-associated macrophages in HNSCC. Methods: We conducted a meta-analysis of the existing publications investigating the relationship between TAMs (total and M2-like subtype) and T stage, nodal involvement, vascular invasion, lymphatic invasion, and tumor differentiation ( Figure 1 ). A total of 12 studies were included. Forest plots and risk ratios were generated to report overall effect. Results: Higher density of both total and M2-like subtype of TAMs in the tumor microenvironment is associated with advanced T stage, increased rates of nodal positivity, presence of vascular invasion, and presence of lymphatic invasion ( p < 0.0001; Figures 2–9 ). There is no significant association between TAM density, either total or M2-like subtype, and tumor differentiation ( Figures 10 , 11 ). Conclusions: Increased density of TAMs, including those of the M2-like phenotype, correlate with poor clinicopathologic markers in HNSCC. Our findings warrant additional investigation into the subpopulations of TAMs, the mechanisms behind their recruitment and differentiation, and the associated influence of each phenotype on tumor growth and invasion. A greater understanding of TAM dynamics in HNSCC is critical for directing further research and employing TAM-targeted adjunct therapies.

show abstract

“…Monoclonal Abs, such as anti-SIRPα Abs, anti-CD47 BRIC126 Abs, and anti-CD47 B6H12 Abs, can promote macrophage phagocytic activity and inhibit tumor cell growth and metastasis. 20 CD47 was found to be a potential therapeutic target for diffuse malignant mesothelioma, and its binding to SIRPα on macrophages can inhibit phagocytosis. 21 Moreover, data on mouse research showed that CD47-CAR-T cells can kill cancer cells, such as ovarian cancer cells and digestive tumor cells.…”

Section: Evolutionmentioning

confidence: 99%

“…Monoclonal Abs, such as anti-SIRPα Abs, anti-CD47 BRIC126 Abs, and anti-CD47 B6H12 Abs, can promote macrophage phagocytic activity and inhibit tumor cell growth and metastasis. 20 …”

Section: Evolutionmentioning

confidence: 99%

<p>Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies</p>

Lu¹,

Chen²,

Wang³

et al. 2020

OTT

View full text Add to dashboard Cite

CD47 belongs to immunoglobulin superfamily and is widely expressed on the surface of cell membrane, while another transmembrane protein SIRPα is restricted to the surface of macrophages, dendritic cells, and nerve cells. As a cell surface receptor and ligand, respectively, CD47 and SIRPα interact to regulate cell migration and phagocytic activity, and maintain immune homeostasis. In recent years, studies have found that immunoglobulin superfamily CD47 is overexpressed widely across tumor types, and CD47 plays an important role in suppressing phagocytes activity through binding to the transmembrane protein SIRPα in phagocytic cells. Therefore, targeting CD47 may be a novel strategy for cancer immunotherapy, and a variety of anti-CD47 antibodies have appeared, such as humanized 5F9 antibody, B6H12 antibody, ZF1 antibody, and so on. This review mainly describes the research history of CD47-SIRPα and focuses on macrophage-mediated CD47-SIRPα immunotherapy of tumors.

show abstract

CD47 is a Potential Target for the Treatment of Laryngeal Squamous Cell Carcinoma

Cited by 12 publications

References 42 publications

Characterization of cluster of differentiationï¿½47 expression and its potential as a therapeutic target in esophageal squamous cell cancer

Characterization of cluster of differentiationï¿½47 expression and its potential as a therapeutic target in esophageal squamous cell cancer

Prognostic Significance of Tumor-Associated Macrophage Content in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis

<p>Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies</p>

Contact Info

Product

Resources

About